Patient-tailored biopsy decisions still maintain high sensitivity<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, April 2, 2024 (HealthDay News) — Prostate biopsies may not be necessary for patients with equivocal or negative magnetic resonance imaging (MRI) results and low prostate-specific antigen density (PSAD), according to a study published online March 29 in\u00a0JAMA Network Open<\/em>.<\/p>\n Arya Haj-Mirzaian, M.D., from Brigham and Women s Hospital in Boston, and colleagues conducted a systematic literature review to determine the optimal prostate biopsy decision-making strategy for avoiding unnecessary biopsies and minimizing the risk for missing clinically significant prostate cancer (csPCa) by combining the MRI Prostate Imaging Reporting & Data System (PI-RADS) and clinical data.<\/p>\n Based on 72 included studies (36,366 patients), the researchers found that PI-RADS category 4 lesions (\u00ce\u00b2-coefficient, 7.82) and category 5 lesions (\u00ce\u00b2-coefficient, 23.18) were significantly associated with a higher risk for csPCa. When considered jointly in a multivariable model, the only clinical variable significantly associated with csPCa besides PI-RADS category 5 lesions (\u00ce\u00b2-coefficient, 9.19) was PSAD (\u00ce\u00b2-coefficient, 15.50). There was a 30 percent reduction in unnecessary biopsies by avoiding biopsy in patients with lesions with PI-RADS category \u00e2\u0089\u00a43 and PSAD <0.10 ng\/mL2<\/sup> compared with performing biopsy in all suspected patients. This strategy had an estimated sensitivity of 97 percent (versus 95 percent with performing biopsy in all suspected patients) and a number needed to harm of 17 (versus 15).<\/p>\n “These findings suggest that in patients with suspected csPCa, patient-tailored prostate biopsy decisions based on PI-RADS and PSAD could prevent unnecessary procedures while maintaining high sensitivity,” the authors write.<\/p>\n